A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

NCT02318368 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Ficlatuzumab
DRUG: Erlotinib
DRUG: placebo

Sponsor

AVEO Pharmaceuticals, Inc.

Collaborators

[object Object]